Document Detail

The optimal therapeutic range for oral anticoagulant treatment as suggested by fibrinopeptide A (FpA) levels in patients with heart valve prostheses.
MedLine Citation:
PMID:  2499477     Owner:  NLM     Status:  MEDLINE    
Fibrinopeptide A is a good marker of in vivo thrombin formation. The aim of oral anticoagulants (OA) is to lower in vivo thrombin formation. We therefore assessed FpA levels on several occasions in 38 patients receiving OA for artificial heart valve prostheses and in 20 patients receiving OA for biological heart valve prostheses. The mean FpA level, 1.82 ng ml-1 (SEM 0.14, n = 176), in patients with artificial valves was significantly higher than the mean, 1.02 ng ml-1 (SEM 0.4), obtained in 41 healthy subjects (P = 0.01). FpA mean value for biological valves was 1.41 ng ml-1 (SEM 0.14, n = 76), which was not significantly higher than controls (P = 0.08). A decrease in FpA levels, for both artificial and biological heart valve prostheses, was associated with a parallel increase in the intensity of anticoagulation. When considering FpA values obtained in the optimal therapeutic range for oral anticoagulant treatment, (International Normalized Ratio [INR] between 3 and 4.5), the mean level for artificial valves, 1.87 ng ml-1 (SEM 0.18, n = 102), was significantly higher than the mean value, 1.25 ng ml-1 (SEM 0.16, n = 55), obtained for biological valves. From a biological point of view, this indicates that artificial valves should be kept at a higher intensity of anticoagulation.
V Pengo; P Peruzzi; M Baca; A Marzari; F Zanon; L Schivapappa; S Dalla Volta
Related Documents :
6478507 - Severe aortic-valve stenosis unmasked by amateur running.
16792467 - Influence of load changes on tricuspid inflow.
10783227 - Relation of changes over time in ventricular size and function to those in exercise cap...
10376477 - Alterations in cardiac morphology and function in elite multi-disciplinary athletes.
12409497 - Changes in locomotor activity parameters with variations in cycle time in larval lamprey.
967937 - Program for cardiac patients: stress testing and training.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of clinical investigation     Volume:  19     ISSN:  0014-2972     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  1989 Apr 
Date Detail:
Created Date:  1989-07-17     Completed Date:  1989-07-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  181-4     Citation Subset:  IM    
Department of Cardiology, Padua University, Padova, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anticoagulants / administration & dosage*
Fibrinogen / metabolism*
Fibrinopeptide A / metabolism*
Heart Valve Prosthesis*
Middle Aged
Thrombin / biosynthesis
Thromboembolism / prevention & control
Reg. No./Substance:
0/Anticoagulants; 25422-31-5/Fibrinopeptide A; 9001-32-5/Fibrinogen; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hypertension in chronic idiopathic glomerulonephritis: analysis of 311 biopsied patients.
Next Document:  Isoforms of creatine kinase: MM in the study of skeletal muscle damage.